Lymphoma News

A greater proportion of patients with cutaneous T-cell lymphoma and sepsis were older, Black and experienced more sepsis episodes compared with patients with sepsis and a different type of non-Hodgkin lymphoma, according to a study.

The addition of first-line brentuximab vedotin to chemotherapy reduced risk for relapse compared with standard treatment among pediatric patients with high-risk Hodgkin lymphoma, according to study results.

The FDA granted fast track designation to MT-101, an investigational chimeric antigen receptor monocyte, for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Three-quarters of patients with advanced B-cell malignancies who received an investigational chimeric antigen receptor T-cell therapy achieved complete response, according to the agent’s manufacturer.

Carl H. June, MD, will receive the inaugural Maria I. New International Prize for Biomedical Research.

Cancer death rates declined broadly between 2015 and 2019 in the United States as overall incidence remained generally stable, according to the Annual Report to the Nation on the Status of Cancer.

Four individuals have been elected to American Society of Hematology’s executive committee.

Emerging evidence has shown chimeric antigen receptor T-cell therapies are highly effective regardless of a patient’s race or ethnicity.

Researchers have discovered a link between neurotoxicity related to chimeric antigen receptor T-cell therapy and development of subsequent hypophosphatemia.

A physical exercise intervention delivered during chemotherapy was associated with a return to similar levels of baseline cardiorespiratory fitness at 1 year compared with exercise after chemotherapy, researchers reported.